# Expansion PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/expansion

> The FDA approved expansion, sponsored by ADMA BIOLOGICS, INC. (ADMA), on December 12, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is expansion FDA approved?

Yes. The FDA approved expansion, sponsored by ADMA BIOLOGICS, INC. (ADMA), on December 12, 2023. SEC Form 10-K: "On December 12, 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the U.S. to now include the pediatric setting for those two years of age and older." [Calendar and source filings](https://sec-api.dev/pdufa/expansion)

Source: SEC Form 10-K, accession 0001140361-25-009257, https://www.sec.gov/Archives/edgar/data/1368514/000114036125009257/ef20038923_10k.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/expansion#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | expansion |
| Codes |  |
| Sponsor | ADMA BIOLOGICS, INC. (ADMA) https://sec-api.dev/companies/adma/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### December 12, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-18, last confirmed 2026-11-04.
- SEC Form 10-K (accession 0001140361-26-006815): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the U.S. to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm
- SEC Form 10-K (accession 0001140361-26-006815): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm
- SEC Form 10-K (accession 0001140361-25-009257): "On December 12, 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the U.S. to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036125009257/ef20038923_10k.htm
- SEC Form 10-Q (accession 0001140361-26-041977): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036126041977/ef20080522_10q.htm
- SEC Form 10-Q (accession 0001140361-26-031445): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036126031445/ef20075111_10q.htm
- SEC Form 10-Q (accession 0001140361-26-019336): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036126019336/ef20070429_10q.htm
- SEC Form 10-Q (accession 0001140361-25-040578): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036125040578/ef20054948_10q.htm
- SEC Form 10-Q (accession 0001140361-25-029177): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036125029177/ef20049201_10q.htm
- SEC Form 10-Q (accession 0001140361-25-017747): "In December 2023, we announced that the FDA approved the expansion of BIVIGAM's label in the United States to now include the pediatric setting for those two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036125017747/ef20047548_10q.htm

### Jun 2025: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-02-25, last confirmed 2026-02-25.
- SEC Form 10-K (accession 0001140361-26-006815): "In June 2025, we filed our supplemental Biologics License Application ("sBLA") for the expansion of ASCENIV's label to include the pediatric setting for patients who are two years and older and we anticipate potential FDA approval of the sBLA in the first half of fiscal year 2026." https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm
- SEC Form 10-K (accession 0001140361-26-006815): "In June 2025, we filed our sBLA for the expansion of ASCENIV's label to include the pediatric setting for patients who are two years and older and we anticipate potential FDA approval in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1368514/000114036126006815/ef20059416_10-k.htm

### May 4, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-05-04, last confirmed 2026-05-04.
- SEC Form 8-K (accession 0001140361-26-018667): "On May 4, 2026, ADMA Biologics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved the Company's label expansion supplemental Biologics License Application for ASCENIVTM to include pediatric immune compromised patients two years of age and older." https://www.sec.gov/Archives/edgar/data/1368514/000114036126018667/ef20072196_8k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/expansion.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Expansion PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/expansion

```bibtex
@misc{secapidev_pdufa_expansion_20261116,
  title        = {Expansion PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/expansion}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_expansion_20261116","title":"Expansion PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/expansion","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
